Aiming at a better understanding of the role of A 2A in temporal lobe epilepsy (TLE), we characterized the effects of the A 2A antagonist SCH58261 (7-(2-phenylethyl)-5-amino-2(2-furyl)-pyrazolo-[4,3-e]-1,2,4-triazolo [1,5-c] pyrimidine) on seizures and neuroprotection in the pilocarpine model. The effects of SCH58261 were further analyzed in combination with the A 1 agonist R-Pia (R(−)-N 6 -(2)-phenylisopropyl adenosine). Eight groups were studied: pilocarpine (Pilo), SCH + Pilo, R-Pia+ Pilo, R-Pia+ SCH + Pilo, Saline, SCH + Saline, R-Pia + Saline, and R-Pia + SCH + Saline. The administration of SCH58261, R-Pia, and R-Pia + SCH58261 prior to pilocarpine increased the latency to SE, and decreased either the incidence of or rate of mortality from SE compared with controls. Administration of R-Pia and R-Pia + SCH58261 prior to pilocarpine reduced the number of Fluoro-Jade B-stained cells in the hippocampus and piriform cortex when compared with control. This study showed that pretreatment with R-Pia and SCH58261 reduces seizure occurrence, although only R-Pia has neuroprotective properties. Further studies are needed to clarify the neuroprotective role of A 2A in TLE.
Introduction
Temporal lobe epilepsy (TLE), the most prevalent type of epilepsy in humans, is characterized by the frequent occurrence of focal epileptiform discharges originating in the temporal region [1] . TLE is frequently associated with loss of pyramidal cells in the prosubiculum, CA1 and CA3 fields, and hilus of the dentate gyrus, as well as with mossy fiber reorganization in the hippocampal formation [2] . The TLE syndrome can be mimicked in rodents as the consequence of status epilepticus (SE) induced by such chemical agents as kainic acid and pilocarpine [3] [4] [5] .
The pilocarpine model mimics several features of human TLE [4, 5] . In this model, systemic administration of high doses of pilocarpine (300-380 mg/kg) generates limbic motor seizures and status epilepticus (SE), which can last up to 12 hours (acute phase). A latent phase, characterized by a seizure-free period lasting approximately 14 days after SE, precedes a chronic phase. The chronic phase is characterized by the occurrence of spontaneous seizures [6] . The pilocarpine model has been widely used in studies exploring antiepileptic agents that either reduce or block neuronal death caused by SE.
Adenosine is a neuromodulator that exerts neuroprotective and anticonvulsant effects in several experimental models of epilepsy, including the pilocarpine model [7, 8] . Adenosine is considered an important target for the treatment of epilepsy, but has many adverse effects when administered systemically [9] . Adenosine can either inhibit or facilitate synaptic transmission through A 1 or A 2A receptors, respectively. By activating A 1 receptors at presynaptic terminals, adenosine can inhibit excitatory amino acid release [10] and block seizures [8] [9] [10] [11] [12] [13] . At the postsynaptic level, the inhibitory effect of the A 1 receptor is mediated by the activation of K + channels and increases in the efflux of K + , which lead to hyperpolarization of postsynaptic neurons [14] [15] [16] . On the other hand, the activation of presynaptic A 2A receptors by high concentrations of extracellular adenosine generated by ATP catabolism during high-frequency stimulation results in an increase in glutamate release [14, 17] . The A 2A pharmacological blockade has been used as a neuroprotective strategy in animal models of ischemia, Parkinson's disease, and Alzheimer's disease [18] [19] [20] [21] [22] , but little is known about the role of A 2A receptors in TLE. Aiming at a better understanding of the role of A 2A in TLE, we characterized the effects of blocking A 2A receptors with the antagonist SCH58261 (7-(2-phenylethyl)-5-amino-2(2-furyl)-pyrazolo-[4,3-e]-1,2,4-triazolo [1,5-c] pyrimidine) on seizure modulation and neuroprotection of the brain areas vulnerable to the injury provoked by pilocarpine. The effects of SCH58261 were further analyzed in combination with the activation of the A 1 receptors by the agonist R-Pia
-(2)-phenylisopropyl adenosine), an effective anticonvulsant and neuroprotective molecule in the pilocarpine model [8, 12] .
Methods

Animals
Adult male Wistar rats weighing approximately 250 g were housed under standard controlled conditions (12-hour light/12-hour dark cycle, 20-22°C, 45-55% humidity), with food and water ad libitum. All animal procedures were conducted in accordance with national and international guidelines (Guidelines of the Brazilian College of Animal Experimentation, COBEA; NIH Guide for Care and Use of Laboratory Animals) and approved by the ethics committee of the university (CEP: 0052/08).
Pilocarpine protocol
Pilocarpine hydrochloride (360 mg/kg, Sigma) was administered intraperitoneally 20 minutes after subcutaneous injection of methylscopolamine (ME) (1 mg/kg, Sigma). ME was used to minimize the peripheral consequences of pilocarpine such as diarrhea, piloerection, olfactory and gustatory automatisms associated with salivation, eye blinking, vibrissa twitching, and yawning, which usually start 5-10 minutes after pilocarpine injection [5] . To standardize the different experimental groups, in all animals receiving pilocarpine, pretreated or not with the adenosinergic agents, SE was stopped at 6 hours by the simultaneous injection of diazepam (10 mg/kg, ip) and pentobarbital (30 mg/kg, ip) [see 23]. Only animals that reached stage 5 of Racine's scale [24] and experienced 6 hours of SE were included in the epileptic group examined 24 hours and 7 days later. Control groups received the same doses of diazepam and pentobarbital, 6 hours after saline injection, and were studied at similar times.
Pharmacological treatments
The adenosinergic A 1 receptor agonist R-Pia (Sigma) was dissolved in dimethylsulfoxide (DMSO, Sigma) and saline, at a ratio of 1:5 (v/v), and a dose of 0.025 mg/kg was given intraperitoneally 15 minutes prior to pilocarpine or saline [8] . 8-p-Sulfophenyl theophylline (8pSPT), an adenosinergic receptor antagonist that does not cross the blood-brain barrier and is used to reduce peripheral effects of adenosine, was given intraperitoneally at the dose of 1.5 mg/kg, simultaneously with R-Pia, but using different syringes [13] . A pilot study performed to test the effect of 8pSPT in the pilocarpine model showed that at this dose, 8pSPT altered neither seizure pattern nor hippocampal neurodegeneration in comparison with rats that received only pilocarpine. The adenosinergic A 2A receptor antagonist SCH58261 (Tocris Bioscience), dissolved in DMSO/saline (1:5, v/v), was administered intraperitoneally at the dose of 0.2 mg/kg 5 minutes prior to pilocarpine or saline [25] . The injection volume was 1 mL/kg body wt. Control animals were given an equivalent volume of the vehicle or saline at the respective time.
Eight groups of rats were studied: Saline (N=5) group rats were injected with saline following DMSO/saline injection; Pilo (N=43) group rats were treated with pilocarpine following DMSO/saline injection; R-Pia+Saline (N=5) animals were treated with saline following coadministration of R-Pia and 8pSPT; R-Pia+Pilo (N=80) animals were treated with pilocarpine following R-Pia+8pSPT injection; SCH+Saline (N=5) animals were treated with saline following SCH58261 injection; SCH+Pilo (N=95) animals were treated with pilocarpine following SCH58261 injection; R-Pia+SCH+Saline (N=5) animals were treated with saline after co-administration of R-Pia, 8pSPT, and SCH58261 given simultaneously; R-Pia+SCH+Pilo (N=94) animals were treated with pilocarpine after co-administration of R-Pia, 8pSPT, and SCH58261.
Behavior
After pilocarpine treatment, latency to the onset of SE, number of animals displaying SE, and mortality rate were evaluated. SE was defined as continuous limbic motor seizures lasting more than 30 minutes [5] .
Perfusion
Rats (N = 5/group) from the eight groups (Pilo, R-Pia + Pilo, SCH + Pilo, R-Pia + SCH + Pilo, and the respective controls Saline, R-Pia + Saline, SCH + Saline; R-Pia + SCH + Saline) were perfused 24 hours and 7 days after SE onset or saline injection, for Fluoro-Jade B analysis. The animals were deeply anesthetized with a solution containing ketamine (80 mg/kg, ip) and xylazine (30 mg/kg, ip). They were fully heparinized before transcardiac perfusion-fixation with saline followed by 4% formaldehyde in 0.1 M phosphate buffer (pH 7.4; 10 mL/ min for 30 min) freshly depolymerized from paraformaldehyde salt. The brain tissue was allowed to fix in situ for 24 hours prior to removal from the skull to achieve full formaldehyde binding, then removed and kept in the same fixative solution (phosphate-buffered formaldehyde 1%) at 4°C until being processed. The brains were sectioned at 40 μm in coronal slices with a vibratome.
Fluoro-Jade B staining
The Fluoro-Jade B (FJ-B) method was used to label dying and "suffering" neurons in brain slices. The brain sections were rinsed in distilled water, mounted on gelatin-coated slides, and immersed in a solution containing 1% sodium hydroxide in 80% ethanol for 5 minutes, then 70% ethanol for 2 minutes and distilled water for 2 minutes. The slides were then incubated in a solution of potassium permanganate 0.06% for 15 minutes and shaken gently on a rotating platform to ensure background suppression between sections. The slides were washed with distilled water for 2 minutes and then incubated with FJ-B staining solution (0.0004% FJ-B diluted in 0.1% acetic acid prepared 10 minutes before use) at room temperature for 30 minutes with gentle shaking. After staining, the slides were rinsed with distilled water, dried in a hot plate at 50°C, dehydrated in ethanol, immersed in xylene, and mounted with Vecta Mount (Vector).
Cell counting
Cell counts were performed in two coronal slices spaced 400 μm apart and stained with FJ-B. FJ-B-positive cells were manually quantified in the dorsal hippocampus (pyramidal layer of CA3 and hilus), piriform cortex (3300-3800 μm posterior to bregma), and entorhinal cortex (4800-5300 μm posterior to bregma), defined according to the atlas of Paxinos and Watson [26] .
Photomicrographs were captured with a PixeLink digital camera connected to a Nikon E600 microscope under a 40× objective and displayed on the 21-in. CRT monitor. A system test (a transparency containing 37 × 37-μm counting frames spaced 47 μm apart) was superimposed on the images. Each counting frame has two lines of inclusion and two of exclusion. All FJ-B-positive cells inside the frame were counted within the delimited fields, except those touching the exclusion lines. At the end, the numbers of cells were summed to obtain the mean total number of FJ-B-positive cells sampled in each area of interest. All stained cells were counted for each set of brain sections by an observer who was experimentally blinded to the treatment groups.
Statistical analysis
Statistical comparisons of latencies and numbers of FJ-B-stained cells (means ± SD) were performed with one-way analysis of variance (ANOVA) followed by adjustment of P values with Bonferroni's post hoc test. A χ 2 test was used to assess treatment effects on incidence of SE, defined as the number of animals with or without identified seizures, and mortality ratio, defined as the number of animals that died following SE. P b 0.05 was considered significant.
Results
Behavior
On administration of pilocarpine + vehicle (N = 43), the majority of the animals (72%) displayed SE within an average of 42 ± 12 minutes and with a mortality rate of 65% (Table 1) . Pretreatment with R-Pia and SCH58261, given alone or simultaneously, prior to pilocarpine, diminished the convulsant effect of pilocarpine. Consequently, an increased number of rats were required in the studied group.
Of 95 rats treated with SCH58261 prior to pilocarpine, only 32% displayed SE with a latency of 58 ± 6 minutes and a mortality rate of 37%. Co-administration of R-Pia prior to pilocarpine (N = 80) resulted in 20% of rats displaying SE after a latency of 74 ± 10 minutes; the mortality rate in this group was 31%. Finally, in the R-Pia + SCH + Pilo group (N = 94), 14% of animals displayed SE after a latency of 80 ± 7 minutes and the mortality rate was 31%. These data are summarized in Table 1 and indicate that administration of the A 1 agonist R-Pia and the A 2A antagonist SCH58261, prior to pilocarpine, increased the resistance of rats to the convulsant effect of pilocarpine.
Evaluation of neuronal degeneration
Positive staining of cells by FJ-B indicates neuronal degeneration. We did not observe any FJ-B-positive cells in the brain areas of the control groups studied 24 hours and 7 days after injection of R-Pia or SCH58261 given prior to saline. However, we observed FJ-B-positive cells in CA3, hilus of the dentate gyrus, amygdala, entorhinal cortex, and piriform cortex, 24 hours and 7 days after the onset of SE, in all experimental groups that received pilocarpine (Table 2) .
Twenty-four hours after SE, there was no statistically significant difference in the number of FJ-B-positive cells in any region between the Pilo and SCH + Pilo groups. By 24 hours, pretreatment with R-Pia or R-Pia + SCH58261 led to a statistically significant reduction in the number of FJ-B-positive cells in CA3 (P b 0.001), hilus of the dentate gyrus (P b 0.01), and piriform cortex (P b 0.001) ( Table 2 , Fig. 1 ). However, there was no significant difference in the number of FJ-Bpositive cells between the R-Pia + Pilo and R-Pia + SCH + Pilo groups (Table 2, Fig. 1 ).
Seven days after the onset of SE, the difference in the number of positive cells between the Pilo and SCH + Pilo groups was not statistically significant. Both the R-Pia and R-Pia + SCH58261 treatments reduced the number of FJ-B-positive cells in CA3 (P b 0.001) and hilus of the dentate gyrus (P b 0.01), in comparison to the pilocarpinetreated group (Fig. 2) . In addition, there was no statistically significant difference in the number of FJ-B positive cells between the R-Pia + Pilo and R-Pia + SCH + Pilo groups (Table 2, Fig. 2 ).
Discussion
Seizure modulation
Adenosine, an endogenous regulator of hippocampal activity, can inhibit or stimulate synaptic transmission via A 1 or A 2A receptors, respectively [10, 14] . Although the antiepileptic properties of the A 1 receptor have been widely reported in scientific studies [9] , relatively little is known concerning the role of A 2A receptors in seizure modulation. The present investigation was undertaken to study this relationship further.
Both, A 2A and A 1 receptors are present in the hippocampus on the glutamatergic terminals [14] . Stimulation of presynaptic A 1 receptors decreases glutamate release, whereas activation of presynaptic A 2A receptors enhances neurotransmitter release [14] . In addition to their presynaptic location in hippocampal neurons, A 2A receptors can be found postsynaptically, where they facilitate depolarization of the membrane [27] . Therefore, the anticonvulsive effect mediated by SCH58261 observed in this study could be due to a decrease in excitatory synaptic transmission in the hippocampus, a decrease in outflow of glutamate from the presynaptic terminal, or a decrease in postsynaptic membrane depolarization. Our findings are in agreement with other studies on the effect of A 2A antagonists in experimental epilepsy models. Porciúncula et al. [28] found that SCH58261 is able to prevent seizures in the kainic acid model. Etherington and Frenguelli [29] showed that another antagonist ligand for the A 2A receptor, ZM241385, reduces epileptiform activity in the hippocampus in vitro. Li and Henry [27] demonstrated that DMPX, another A 2A antagonist, is able to block the depolarization effects provoked by CGS21680, an A 2A agonist, in the hippocampus in in vitro assays. A 2A -deficient mice were not protected against seizures originating from brainstem structures, but displayed a significant reduction in the intensity of seizures as well as in the number of mice developing limbic seizures induced by pilocarpine [30] . On the other hand, previous studies by our group using the A 2A antagonist DMPX given prior to pilocarpine showed that this A 2A antagonist reduces the latency to the onset of seizures in the majority of animals and increases the number of apoptotic cells in the hippocampus of rats displaying SE [8] . These opposite effects of A 2A antagonists, as compared with those described in the literature [21, 25, 31] , could be related to the specificity, the dose used, and the different models.
In the present study, we also observed the anticonvulsive effect of R-Pia, an A 1 receptor agonist. This effect is in agreement with the current literature that describes the inhibitory effect of the A 1 receptor on ictal activity [8, 9, 11, 13, 32] . The hippocampus has high A 1 receptor density localized both pre-and postsynaptically [14] . Presynaptic activation of this receptor modulates excitatory synaptic transmission by decreasing glutamate release through the inhibition of voltagedependent Ca 2+ channels. In parallel, postsynaptic activation reduces neuronal excitability by increasing membrane conductance to K + ions, thereby causing hyperpolarization of the cell [10, 14, 15] . Our results-significant reductions in the percentages of animals that exhibited SE after each pharmacological treatment and in mortality rates after the insult-are in agreement with the known effect of modulation of glutamatergic neurotransmission by A 1 and A 2A adenosine receptors. The latter effect leads to reduced sensitivity to pilocarpine and less deleterious consequences of SE translating into lower mortality rates after pilocarpine-induced seizures.
Neuroprotection of brain areas that are vulnerable to injury
Analysis of the pattern of FJ-B staining in animals treated with pilocarpine demonstrated substantial neurodegeneration in CA3, hilus of the dentate gyrus, basolateral amygdala, entorhinal cortex, and piriform cortex, 24 hours and 7 days after the insult. FJ-B has been used as a fluorescence marker for neurodegeneration caused by both pilocarpine and lithium-pilocarpine. Fabene et al. [33] found a large number of FJ-B-positive neurons in the hippocampus 8 and 24 hours after SE induced with pilocarpine [33] . Voutsinos-Porche et al. [34] reported the presence of FJ-B-positive cells in several brain regions analyzed in the acute (12 and 24 hours after the SE) and latent (3 and 6 days after SE) phases of the lithium-pilocarpine model. The neuronal death observed in the pilocarpine model can be triggered by various mechanisms, especially excitotoxicity. Prolonged SE causes the activation of excitotoxic cascades in which Ca 2+ ions are key mediators. Once activated, these cascades lead to an excessive release of glutamate that acts on kainate, AMPA, and NMDA receptors, promoting a massive Ca 2+ influx into the cell that triggers activation of proteases, lipases, and endonucleotidases culminating in cell death [35] . The present work also showed that SCH58261 pretreatment did not alter the pattern of FJ-B labeling of cells in the brain regions studied when compared with pilocarpine alone. Thus, the A 2A antagonist failed to confer neuroprotection in the pilocarpine model of TLE. These results are not in line with several reports employing different noxious brain stimuli that demonstrated the ability of A 2A receptor blockade to confer neuroprotection [14, 25, [36] [37] [38] . Some authors used A 2A receptor antagonists in the kainic acid model of neurotoxicity [39, 40] or in a model of cerebral ischemia [31] and reported robust neuroprotection, particularly in the areas (i.e., cortex) where the density of these receptors is much lower than in basal ganglia [41] [42] [43] . In fact, A 2A receptors can be upregulated during prolonged seizures and this response is most evident in extrastriatal regions (i.e., cortical area) [24] .
On the other hand, SCH58261 combined with R-Pia led to neuroprotection in the hilus, CA3, and piriform cortex, suggesting that this effect must have occurred as a result of A 1 receptor inhibition.
In fact, it appears that the neuroprotective effect of A 1 receptors is relevant at the onset of brain damage [14] , and our data confirm this statement. Our data do not support an upregulation of A 2A receptors at the time when the rats were studied. However, we suggest that our data could be related to the dose of SCH58261 employed in this study. Some authors have reported that the dose of this A 2A receptor antagonist necessary to be effective in conferring neuroprotection is very low (nanomolar) and the neuroprotective effect could be lost with increasing dosages, that is, 1 mg/kg [18, 21, 25] . At high doses (i.e., millimolar), SCH58261 can block adenosine A 2A receptor-mediated effects on blood pressure, reducing blood and nutrient supply to the compromised brain areas and further stimulating glutamate release [39, 44] . The dose of SCH58261 used in the present study was an intermediate dose reported by Popoli and co-workers [25] as effective against the excitotoxic effects of quinolinic acid, that is, 0.2 mg/kg.
It must also be remembered that in the hippocampus, A 1 receptors are present on the presynaptic terminals and on the soma of postsynaptic neurons, whereas A 2A receptors are present mainly on presynaptic terminals [14] . The striatum contains A 2A receptors postsynaptically, but in the hippocampus, their postsynaptic localization is minimal. Therefore, use of an A 2A antagonist such as SCH58261 can be expected to block glutamate release in the hippocampus, but will not prevent activation of postsynaptic glutamate receptors. This dual effect might explain why pyramidal neurons were not protected by the A 2A antagonist in the present study. In contrast, activating A 1 receptors will block glutamate release and activation of postsynaptic glutamate receptors involved in excitotoxicity. Furthermore, activation of A 1 receptors blocks the release of glutamate, but not of GABA, whereas A 2A activation increases release of glutamate and GABA. Therefore, blocking A 2A receptors will block the release of glutamate and GABA, which might precipitate SE as observed in the present study and by other groups [14] .
To clarify the contradictory findings regarding the potential neuroprotective effect of the A 2A receptor in the pilocarpine model, a new study using lower doses (nanomolar) of SCH58261 will be performed. One of the possible mechanisms involved in the genesis of the injury process triggered by SE is the imbalance between cerebral glucose consumption and blood flow that occurs during severe epileptic seizures or SE [45] , where A 2A receptors could play a role. These receptors are present in cerebral blood vessels and can promote vasodilation and self-regulation of cerebral blood flow [46] , suggesting that A 2A receptors might be directly contributing to the neurodegenerative process. By inhibiting A 2A receptors, SCH58261 might alter blood flow homeostasis in the brain, worsening the imbalance between the metabolic demand and the energy supply during SE.
The administration of R-Pia prior to pilocarpine reduced FJ-B labeling in CA3, hilus of the dentate gyrus, and piriform cortex. This finding is in agreement with the literature concerning the neuroprotective properties triggered by the utilization of A 1 agonists in epilepsy models [8, 12, 22] . Activation of these receptors reduces the release of glutamate, inhibits NMDA receptors, and causes hyperpolarization on the neuronal membrane [14] . These effects are crucial to the intracellular Ca 2+ homeostasis maintenance mediated by A 1 receptors. In addition, injection of this A 1 receptor agonist prior to pilocarpine reduces the uncoupling between local cerebral blood flow and glucose metabolism caused by SE, resulting in neuroprotection [47] .
Conclusion
This study showed that the A 2A antagonist SCH58261 is not neuroprotective when administered prior to pilocarpine. Further studies aimed at clarifying the apparent discrepancy between the neuroprotective effects of A 2A antagonists in different models of neurotoxicity and lack thereof in the pilocarpine model of temporal lobe epilepsy are warranted.
